Investigational Drug Information for MK-3682
✉ Email this page to a colleague
What is the development status for investigational drug MK-3682?
MK-3682 is an investigational drug.
There have been 8 clinical trials for MK-3682.
The most recent clinical trial was a Phase 2 trial, which was initiated on December 10th 2015.
The most common disease conditions in clinical trials are Hepatitis C, Hepatitis A, and Hepatitis. The leading clinical trial sponsors are Merck Sharp & Dohme Corp. and [disabled in preview].
There are six US patents protecting this investigational drug and one hundred and twenty-two international patents.
Summary for MK-3682
US Patents | 6 |
International Patents | 122 |
US Patent Applications | 21 |
WIPO Patent Applications | 14 |
Japanese Patent Applications | 2 |
Clinical Trial Progress | Phase 2 (2015-12-10) |
Vendors | 4 |
Recent Clinical Trials for MK-3682
Title | Sponsor | Phase |
---|---|---|
Efficacy and Safety of Uprifosbuvir (MK-3682) + Ruzasvir (MK-8408) in Treating Hepatitis C Virus Infection Genotypes 1-6 (MK-3682-041) | Merck Sharp & Dohme Corp. | Phase 2 |
Efficacy and Safety of Uprifosbuvir (MK-3682) With Ruzasvir (MK-8408) in Adults With Chronic Hepatitis C Genotype 1, 2, 3, 4, 5 or 6 Infection (MK-3682-035) | Merck Sharp & Dohme Corp. | Phase 2 |
A Study of the Pharmacokinetics of Uprifosbuvir (MK-3682) and Ruzasvir (MK-8408) in Participants With Moderate and Severe Hepatic Insufficiency (MK-3682-029) | Merck Sharp & Dohme Corp. | Phase 1 |
Clinical Trial Summary for MK-3682
Top disease conditions for MK-3682
Top clinical trial sponsors for MK-3682
US Patents for MK-3682
Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
---|---|---|---|---|
MK-3682 | See Plans and Pricing | Process for making chloro-substituted nucleoside phosphoramidate compounds | Merck Sharp & Dohme Corp. (Rahway, NJ) | See Plans and Pricing |
MK-3682 | See Plans and Pricing | Process for making nucleoside phosphoramidate compounds | Merck Sharp & Dohme Corp. (Rahway, NJ) Idenix Pharmaceuticals LLC (Cambridge, MA) | See Plans and Pricing |
MK-3682 | See Plans and Pricing | 2'-chloro nucleoside analogs for HCV infection | IDENIX PHARMACEUTICALS LLC (Cambridge, MA) CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (Paris, FR) UNIVERSITE DE MONTPELLIER (Montpellier, FR) | See Plans and Pricing |
>Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for MK-3682
Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
---|---|---|---|---|
MK-3682 | World Intellectual Property Organization (WIPO) | WO2016064797 | 2034-10-20 | See Plans and Pricing |
MK-3682 | African Regional IP Organization (ARIPO) | AP3913 | 2032-05-22 | See Plans and Pricing |
MK-3682 | Argentina | AR092835 | 2032-05-22 | See Plans and Pricing |
>Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |